Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

TriSalus Life Sciences (TLSIW) Equity Ratio (2022 - 2025)

TriSalus Life Sciences' Equity Ratio history spans 4 years, with the latest figure at 0.96 for Q4 2025.

  • For Q4 2025, Equity Ratio rose 11.28% year-over-year to 0.96; the TTM value through Dec 2025 reached 0.96, up 11.28%, while the annual FY2025 figure was 0.96, 11.28% up from the prior year.
  • Equity Ratio reached 0.96 in Q4 2025 per TLSIW's latest filing, down from 0.73 in the prior quarter.
  • In the past five years, Equity Ratio ranged from a high of 0.25 in Q3 2023 to a low of 16.21 in Q2 2023.
  • Average Equity Ratio over 4 years is 2.74, with a median of 0.87 recorded in 2024.
  • The largest YoY upside for Equity Ratio was 140.35% in 2023 against a maximum downside of 2683.27% in 2023.
  • A 4-year view of Equity Ratio shows it stood at 8.05 in 2022, then skyrocketed by 86.34% to 1.1 in 2023, then increased by 1.82% to 1.08 in 2024, then grew by 11.28% to 0.96 in 2025.
  • Per Business Quant, the three most recent readings for TLSIW's Equity Ratio are 0.96 (Q4 2025), 0.73 (Q3 2025), and 0.47 (Q2 2025).